---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024472"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:35:23.320470+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Janux Q3 net loss $16.7M; first patient dosed in JANX007 Phase 1 trial

## Summary
- Q3 2022 net loss of $16.7M vs $10.8M prior year; R&D spend $13.7M (up from $8.4M).
- Cash and short-term investments $338.8M at Sep 30, 2022, down from $375.0M at Dec 31, 2021.
- First patient dosed with JANX007 in Phase 1 trial for prostate cancer; interim data expected 2H 2023.
- IND for EGFR-TRACTr (JANX008) on track for 2H 2022; PD-L1xCD28 TRACIr (JANX009) IND planned for 2023.
- Strengthened management with new HR head and board addition Winston Kung.

## SEC filing metadata
- accession: 0000950170-22-024472
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017022024472/0000950170-22-024472-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017022024472/janx-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024472
- JSON: https://secwatch.observer/filing/0000950170-22-024472.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024472.txt

## Key facts
- Earnings Releases
  Janux Therapeutics, Inc. reported financial results for the three and nine months ended September 30, 2022.
  - Period: the three and nine months ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017022024472/0000950170-22-024472-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.